Alkermes plc (FRA:8AK)

Market Cap	4.21B
Revenue (ttm)	1.30B
Net Income (ttm)	288.78M
Shares Out	n/a
EPS (ttm)	1.72
PE Ratio	14.59
Forward PE	14.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154
Average Volume	2
Open	24.40
Previous Close	24.00
Day's Range	24.40 - 24.40
52-Week Range	22.00 - 34.60
Beta	n/a
RSI	52.61
Earnings Date	Feb 13, 2026

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable su...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 1,800
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8AK

Financial Performance

In 2024, Alkermes's revenue was $1.56 billion, a decrease of -6.36% compared to the previous year's $1.66 billion. Earnings were $367.07 million, an increase of 3.18%.

Financial numbers in USD